InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,025.25
(
-0.21%
)
US TECH 100
16,880.85
(
-0.60%
)
Dow Jones
37,939.46
(
0.33%
)
Brent Oil
83.41
(
-2.90%
)
Bitcoin
57,406.13
(
-5.29%
)
Post# of 251661
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119527
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 199657

Wednesday, 11/16/2016 5:24:48 PM

Wednesday, November 16, 2016 5:24:48 PM

Post# of 251661
GILD’s Momelotinib goes 1-for-2 in SIMPLIFY/1-2 trials: #msg-126609986.

http://finance.yahoo.com/news/gilead-announces-top-line-results-211500046.html

The nominal success was in SIMPLIFY-1, where Momelotinib was non-inferior to Jakafi in JAK-naïve patients.

The failure was in SIMPLIFY-2, where Momelotinib was not superior to BAT (Best Available Therapy) in patients previously treated with—but not refractory to—Jakafi.

Momelotinib is the drug GILD picked up in the 2012 buyout of YMI (#msg-82377008).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up